急性冠脉综合征后45天内院内流感疫苗接种预防心肺事件:VIP-ACS试验的预设分析
VIP-ACS为随机、实用、多中心、开放标签、盲法裁定终点的试验,纳入1801例急性冠脉综合征住院≤7天的患者,比较院内双倍剂量四价灭活流感疫苗与随机化后30天标准剂量疫苗接种。主要终点为死亡、心梗、卒中、不稳定心绞痛住院、心衰住院、紧急冠脉血运重建和呼吸道感染住院的层级复合终点,45天随访时双倍剂量组与标准剂量组无显著差异(WR 1.03,95%CI 0.70-1.53,P=0.85),未观察到严重不良事件。
要点
- 急性冠脉综合征后45天内,院内双倍剂量流感疫苗与延迟标准剂量相比未显著减少心肺事件。
- 主要终点双倍剂量组胜率5.7% vs 标准剂量组5.5%(WR 1.03,95%CI 0.70-1.53,P=0.85)。
- 未观察到严重不良事件。
核心结论
- 近期急性冠脉综合征患者中,院内双倍剂量流感疫苗接种与随机化后30天标准剂量疫苗接种相比,未显著减少45天时的心肺事件。
研究设计与样本
- VIP-ACS为随机、实用、多中心、开放标签、盲法裁定终点的试验,纳入1801例年龄≥18岁、急性冠脉综合征住院≤7天的患者。
- 患者随机分为院内双倍剂量四价灭活流感疫苗组或随机化后30天标准剂量流感疫苗组。
主要发现
- 主要层级复合终点(死亡、心肌梗死、卒中、不稳定心绞痛住院、心力衰竭住院、紧急冠状动脉血运重建和呼吸道感染住院)双倍剂量组胜率5.7% vs 标准剂量组5.5%(WR 1.03;95%CI 0.70-1.53;P=0.85)。
- 将COVID-19感染纳入呼吸道感染住院终点的敏感性分析结果一致(WR 1.03;95%CI 0.71-1.51;P=0.87)。
- 仅主要心血管事件终点结果一致(WR 0.82;95%CI 0.48-1.39;P=0.46)。
- 未观察到严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza vaccination prevents major cardiovascular events in individuals presenting a recent acute coronary syndrome (ACS), however the early effect of an in-hospital double-dose vaccination strategy remains uncertain. METHODS: The VIP-ACS was a randomized, pragmatic, multicenter, open-label trial with a blinded-adjudication endpoint. Patients with ACS ≤ 7 days of hospitalization were randomized to an in-hospital double-dose quadrivalent inactivated influenza vaccine (double-dose) or a standard-dose influenza vaccine at 30 days post-randomization. The primary endpoint was a hierarchical composite of death, myocardial infarction, stroke, hospitalization for unstable angina, hospitalization for heart failure, urgent coronary revascularization, and hospitalization for respiratory infections, analyzed with the win ratio (WR) method in short-term follow-up (45-days after randomization). RESULTS: The trial enrolled 1,801 patients (≥18 years old). Median participant age was 57 years, 70 % were male. There were no significant differences between groups on the primary hierarchical endpoint: there were 5.7 % wins in the double-dose in-hospital group and 5.5 % wins in the standard-dose delayed vaccination group (WR: 1.03; 95 % CI: 0.70---1.53; P = 0.85). In a sensitivity analysis including COVID-19 infection in the hospitalizations for respiratory infections endpoint, overall results were maintained (WR: 1.03; 95 % CI 0.71---1.51; P = 0.87). Results were consistent for major cardiovascular events only (WR: 0.82; 95 % CI: 0.48---1.39; P = 0.46). No serious adverse events were observed. CONCLUSION: In patients with recent ACS, in-hospital double-dose influenza vaccination did not significantly reduce cardiorespiratory events at 45 days compared with standard-dose vaccination at 30 days post-randomization.
引用
- Fonseca HAR, Zimerman A, Monfardini F, et al. In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial. Vaccine. 2023. PMID: 38154990. doi:10.1016/j.vaccine.2023.12.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。